Evidence map›Paper›PMID 36588335›Full record

ArticleCurrent Alzheimer research2023

Development and Psychometric Validation of the 27 Item Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD-27).

Coen A Bernaards, Kathrin I Fischer, Angela J Rylands, Adam Gater, Chloe Tolley, Steven H Zarit, Claire J Lansdall

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Current Alzheimer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01677754 (A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01677754 phase2completednot on this map

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease

TypeinterventionalSponsorHoffmann-La RocheRan2012 to 2015Enrolled542ConditionsAlzheimer's DiseaseArmsRO4602522, Placebo, Donepezil, Memantine, Rivastigmine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Coen A BernaardsDepartment of Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.
Kathrin I FischerPatient Centered Outcomes Research, Roche Products Limited, Welwyn Garden City, UK.
Angela J RylandsPatient Centered Outcomes Research, Roche Products Limited, Welwyn Garden City, UK.
Adam GaterPatient Centered Outcomes Research, Adelphi Values, Bollington, UK.
Chloe TolleyPatient Centered Outcomes Research, Adelphi Values, Bollington, UK.
Steven H ZaritDepartment of Human Development and Family Studies, The Pennsylvania State University, University Park, PA, USA.
Claire J LansdallCentered Outcomes Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Adelphi Group (United Kingdom) · GBRoche (United Kingdom) · GBPennsylvania State University · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCaring for an individual with Alzheimer's disease (AD) is an allencompassing challenge that affects daily life. Assessment of the care partner experience is needed to support the development and evaluation of successful interventions for people with AD and their care partners. We developed the 27-item Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD-27) to assess the impact of informal caregiving in the context of AD.

objectiveWe assessed the psychometric validity of the ZCI-AD-27 in a population of care partners for individuals with moderate AD, and established thresholds for meaningful score change.

methodsSecondary data were obtained from informal care partners of participants in a clinical trial (NCT01677754). Psychometric analyses were conducted to assess validity, reliability, and responsiveness of the ZCI-AD-27. Anchor-based and distribution-based methods were performed to determine clinically meaningful score change.

resultsThe ZCI-AD-27 had a 12-domain factor structure, including a second-order domain termed Humanistic impact that included four key domains (Physical, Emotional, Social, and Daily life) as confirmed by confirmatory factor analysis with the adequate fit. Internal consistency (Cronbach's alpha ranging from 0.66 to 0.93 for domains), convergent validity, and discriminant validity indicated the good performance of the ZCI-AD-27. Known-groups validity analyses showed a greater impact on care partners with increasing disease severity. Responsiveness results demonstrated that the ZCI-AD- 27 is sensitive to change over time and meaningful change analyses indicated a range of meaningful score changes in this population.

conclusionThe ZCI-AD-27 is a comprehensive, psychometrically valid measure to assess the impact of caring for individuals with moderate AD.

Indexed as

Alzheimer DiseaseCaregiversHumansPsychometricsReproducibility of ResultsSurveys and QuestionnairesAlzheimer’s diseasecaregivercaregiverreported outcomespsychometricsvalidationZarit Burden InterviewZarit Caregiver Interview

Identifiers

PMID36588335
PMCPMC10278238
OpenAlexW4313382425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.